Assessment of the impact of Japanese‐specific long‐term safety data on new drug approval
Abstract Under the International Council for Harmonization (ICH)‐E1 guideline for drugs intended for chronic or repeated intermittent use in non‐life‐threatening diseases, data from 100 patients exposed for a minimum of 1 year are required to be included in the safety data base of a new drug applica...
Guardado en:
Autores principales: | Shinobu Uzu, Shohko Sekine, Junichi Asano, Mutsuhiro Ikuma |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Wiley
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/4f110dba9e164384af91d02ec52ee583 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Pharmacometric analyses of alectinib to facilitate approval of the optimal dose for the first‐line treatment of anaplastic lymphoma kinase–positive non‐small cell lung cancer
por: Joy C. Hsu, et al.
Publicado: (2021) -
Melatonergic drugs in development
por: Carocci A, et al.
Publicado: (2014) -
Single- and multiple-dose pharmacokinetics, pharmacodynamics, and safety of apixaban in healthy Chinese subjects
por: Cui Y, et al.
Publicado: (2013) -
Scientific and regulatory evaluation of mechanistic in silico drug and disease models in drug development: Building model credibility
por: Flora T. Musuamba, et al.
Publicado: (2021) -
Exposure–response analysis of efficacy and safety for pexidartinib in patients with tenosynovial giant cell tumor
por: Ophelia Yin, et al.
Publicado: (2021)